(+/-)-xestoquinone | 97743-96-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: (+/-)-xestoquinone
• 英文别名: 1-methyl-14-oxapentacyclo[11.6.1.02,11.04,9.016,20]icosa-2(11),3,6,9,13(20),15-hexaene-5,8,12-trione
• CAS: 97743-96-9
• 化学式: C₂₀H₁₄O₄
• 分子量: 318.329
• InChiKey: HDONDRKCXFRHQQ-UHFFFAOYSA-N

物化性质

• 密度：
  1.415

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  亚牛磺酸 、 (+/-)-xestoquinone 以 乙醇 、 乙腈 为溶剂， 反应 0.02h， 以14 mg的产率得到adociaquinone B
  参考文献：
  名称：

  Xesto- and halenaquinone derivatives from a sponge, Adocia sp., from Truk lagoon

  摘要：

  DOI：

  10.1021/jo00252a007
• 作为产物：
  描述：

  4,7-dimethoxybenzofuran 在 palladium on activated charcoal ammonium cerium(IV) nitrate 、 氢气 、 sodium 、 四氯苯醌 、 碳酸氢钠 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 甲苯 、 乙腈 、 xylene 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 98.83h， 生成 (+/-)-xestoquinone
  参考文献：
  名称：

  Isobenzofurans and ortho-benzoquinone monoketals in syntheses of xestoquinone and its 9- and 10-methoxy derivatives

  摘要：

  Syntheses of (+/-)-xestoquinone, (+/-)-9-methoxyxestoquinone and (+/-)-10-methoxyxestoquinone are described. A convergent CD plus ABE plan using the appropriate isobenzofuran (CD) and naphthofuranone (ABE) has been implemented to provide these marine metabolites in overall yields of 18.3, 9.5 and 8.5%, respectively. The latter pair of compounds, previously evaluated as inhibitors of Topoisomerase II as an inseparable mixture, are now available separate and pure for the first time. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(00)00938-8

文献信息

• [EN] INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS<br/>[FR] INHIBITEURS DE LA INDOLEAMINE 2,3-DIOXYGENASE (IDO)
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2006005185A1

  公开（公告）日：2006-01-19

  Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacteria/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.

  提供了吲哚胺2,3-二氧化酶（IDO）的抑制剂，包括含有这些抑制剂的药物组合物，以及利用这些抑制剂和组合物治疗哺乳动物主体中的一种病况的用途，该病况的特征是IDO介导的色氨酸代谢通路的病理。这些病况可能涉及抑制T细胞介导的免疫应答，或者可能直接由色氨酸耗竭或色氨酸降解产物积累导致。具体的疾病条件包括白内障、眼睛的老化黄斑、神经退行性疾病、情绪障碍、癌症以及各种细菌/病毒感染。本发明的IDO抑制剂是取代萘和蒽二酮。本发明的新化合物包括以下的牛磺酸取代萘醌结构。
• Therapeutic agent elution control process
  申请人：Cordis Corporation

  公开号：EP1891991A2

  公开（公告）日：2008-02-27

  Implantable coated medical devices may be processed through annealing to better control the elution characteristics of the therapeutic agents. Furthermore, annealing leads to better therapeutic agent stability and a larger device shelf-life.

  植入式涂层医疗器械可通过退火处理来更好地控制治疗剂的洗脱特性。此外，退火还能提高治疗剂的稳定性，延长设备的保质期。
• Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, AAA and stroke
  申请人：Cordis Corporation

  公开号：EP1974758A2

  公开（公告）日：2008-10-01

  Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organismfi reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic agents or compounds may also further reduce a biological organismis, reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

  医疗器械，尤其是植入式医疗器械，可以进行涂层处理，以尽量减少或基本消除生物体对医疗器械进入生物体后产生的反应。医疗器械可涂覆各种生物相容性材料。治疗药物、药剂或化合物可与生物相容性材料混合，并粘附在医疗设备的至少一部分上。这些治疗剂或化合物还可进一步降低生物体对医疗器械进入生物体后的反应。此外，这些治疗药物、制剂和/或化合物还可用于促进愈合，包括预防血栓形成。这些药物、制剂和/或化合物还可用于治疗特定疾病，包括易损斑块。治疗剂也可输送到疾病部位的区域。在区域性给药中，液体制剂可能是提高特定药物疗效和可给药性的理想选择。此外，还可对装置进行改良，以促进内皮化。可利用各种材料和涂层方法将药剂或化合物保持在医疗器械上，直至输送和定位。此外，还可对用于递送植入式医疗器械的装置进行改良，以降低在递送过程中损坏植入式医疗器械的可能性。医疗器械包括支架、移植物、吻合器、血管周围包裹物、缝合线和订书钉。此外，还可利用各种聚合物组合来控制治疗药物、制剂和/或化合物从植入式医疗器械中的洗脱率。
• Local vascular delivery of mTor inhibitors in combination with peroxisome proliferators-activated receptor stimulators
  申请人：Cordis Corporation

  公开号：EP2042202A2

  公开（公告）日：2009-04-01

  Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including vulnerable plaque, and athereosclerosis in type 2 diabetic patients. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

  医疗器械，尤其是植入式医疗器械，可以进行涂层处理，以尽量减少或基本消除生物体对医疗器械进入生物体后的反应。医疗器械可涂覆各种生物相容性材料。治疗药物、药剂或化合物可与生物相容性材料混合，并粘附在医疗设备的至少一部分上。这些治疗剂或化合物还可进一步降低生物机体对医疗器械进入生物机体的反应。此外，这些治疗药物、制剂和/或化合物还可用于促进愈合，包括预防血栓形成。这些药物、制剂和/或化合物还可用于治疗特定疾病，包括易损斑块和 2 型糖尿病患者的动脉粥样硬化。治疗剂也可输送到疾病部位的区域。在区域给药中，液体制剂可能是提高特定药物疗效和可给药性的理想选择。此外，还可对装置进行改良，以促进内皮化。可利用各种材料和涂层方法将药剂或化合物保持在医疗器械上，直至输送和定位。此外，还可对用于递送植入式医疗器械的装置进行改良，以降低在递送过程中损坏植入式医疗器械的可能性。此外，还可利用各种聚合物组合来控制治疗药物、药剂和/或化合物从植入式医疗器械中的洗脱率。
• Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices
  申请人：Cordis Corporation

  公开号：EP2095833A2

  公开（公告）日：2009-09-02

  Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including vulnerable plaque, and atherosclerosis in type 2 diabetic patients. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned.

  医疗器械，尤其是植入式医疗器械，可以进行涂层处理，以尽量减少或基本消除生物体对医疗器械进入生物体后的反应。医疗器械可涂覆各种生物相容性材料。治疗药物、药剂或化合物可与生物相容性材料混合，并粘附在医疗设备的至少一部分上。这些治疗剂或化合物还可进一步降低生物机体对医疗器械进入生物机体的反应。此外，这些治疗药物、制剂和/或化合物还可用于促进愈合，包括预防血栓形成。这些药物、制剂和/或化合物还可用于治疗特定疾病，包括易损斑块和 2 型糖尿病患者的动脉粥样硬化。还可将治疗剂输送到疾病部位的区域。在区域给药中，液体制剂可能是提高特定药物疗效和可给药性的理想选择。可利用各种材料和涂层方法将药剂或化合物保持在医疗设备上，直至输送和定位。